Nephros touts ultrafiltration tech as microplastic risk gains EPA focus
Nephros has moved to capitalise on growing regulatory concern about microplastic contamination in drinking water, highlighting that its existing ultrafiltration technology is already capable of physically excluding both micro- and nanoplastic particles from water supplies.
The South Orange, New Jersey company pointed to the US Environmental Protection Agency's April 2026 decision to include microplastics as a priority contaminant group under the draft Contaminant Candidate List 6 (CCL 6), issued under the Safe Drinking Water Act, as a market signal validating its product positioning. The CCL designation does not impose mandatory limits but identifies contaminants for further regulatory scrutiny, making it an early-stage indicator of eventual enforceable standards.
The technology case
Nephros' ultrafiltration membranes are engineered with pore sizes as small as 5 nanometres, well below the lower threshold of nanoplastics, which the company defines as particles smaller than 1 micrometre. Conventional filtration systems, including many carbon block and sand filters widely used in municipal and point-of-use settings, operate at pore sizes orders of magnitude larger and are not designed to intercept particles at this scale.
The company says the same size-based exclusion mechanism that allows its filters to retain bacteria and viruses also makes them effective against plastic particles, without requiring product reformulation or new regulatory clearances. Robert Banks, president and chief executive of Nephros, said the capability "further differentiates Nephros in both healthcare and broader water quality markets," adding that the convergence of scientific and regulatory attention was creating new urgency for high-performance filtration.
Nephros serves healthcare settings, including hospitals and dialysis facilities where water purity is already subject to strict oversight, as well as commercial markets. The company is listed on Nasdaq under the ticker NEPH.
Market and regulatory context
The broader water filtration market has been watching the microplastics question with considerable interest. A series of peer-reviewed studies published in 2025 and 2026, including work in Nature Medicine and The Lancet Planetary Health, has linked nanoplastic exposure to potential systemic health effects, and one study cited by Nephros examined plastic particle accumulation in human brain tissue. That body of evidence is likely to accelerate regulatory timelines beyond the CCL framework.
Nephros is not alone in recognising the commercial opportunity. Several larger water treatment companies, including those operating in municipal infrastructure and industrial process water, have either launched or signalled development of sub-micron filtration products aimed at the microplastics segment. Point-of-use ultrafiltration is a relatively mature technology in healthcare water management, but its application as a consumer or commercial microplastics solution is newer and less well validated in real-world deployment data.
The EPA's CCL 6 process typically precedes a regulatory determination on whether to initiate formal rulemaking, a process that can take years. Nephros is effectively making a positioning argument ahead of hard regulation, which is commercially rational but carries the risk that enforceable standards, if they arrive, may prescribe performance criteria that diverge from the company's current product specifications.
Near-term, investors will be watching whether the regulatory narrative converts to incremental revenue, particularly in commercial accounts outside the company's core healthcare base. Nephros has not disclosed specific pipeline deals, contract wins, or revenue guidance linked to the microplastics opportunity.